Evidence map›Paper›PMID 42374450›Full record

ArticleBMC medicine2026

An ICOSL-armed oncolytic adenovirus activates CD4

Wencui Liu, Xuanqi Ren, Yuxin Zhang, Qian Yue, Xiangmei Chen, Dan Zhou, Xiao Li, Qilei Xin, Lingkai Kong, Hao Wu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Wencui Liu *Jinan Microecological Biomedicine Shandong Laboratory, Shandong First Medical University, Jinan, 250117, China.
Xuanqi Ren *State Key Laboratory of Pharmaceutical Biotechnology, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Suqian Scientific Research Institute of Nanjing University Medical School, Medical School, Nanjing University, Nanjing, 210008, China.
Yuxin Zhang *State Key Laboratory of Pharmaceutical Biotechnology, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Suqian Scientific Research Institute of Nanjing University Medical School, Medical School, Nanjing University, Nanjing, 210008, China.
Qian Yue *Jinan Microecological Biomedicine Shandong Laboratory, Shandong First Medical University, Jinan, 250117, China.
Xiangmei ChenJinan Microecological Biomedicine Shandong Laboratory, Building 1, Jinan Medical and Health Science and Technology Innovation Industrial Park, Jinan, 250000, China.
Dan ZhouState Key Laboratory of Pharmaceutical Biotechnology, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Suqian Scientific Research Institute of Nanjing University Medical School, Medical School, Nanjing University, Nanjing, 210008, China.
Xiao LiJinan Microecological Biomedicine Shandong Laboratory, Building 1, Jinan Medical and Health Science and Technology Innovation Industrial Park, Jinan, 250000, China.
Qilei XinJinan Microecological Biomedicine Shandong Laboratory, Building 1, Jinan Medical and Health Science and Technology Innovation Industrial Park, Jinan, 250000, China.
Lingkai KongState Key Laboratory of Pharmaceutical Biotechnology, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Suqian Scientific Research Institute of Nanjing University Medical School, Medical School, Nanjing University, Nanjing, 210008, China.
Hao WuRegional University-Industry Technology Transfer Center for Biopharmaceuticals (Nanjing, Jiangsu), 141 Longshan South Road, Pukou District, Nanjing, China.
Ciliang GuoState Key Laboratory of Pharmaceutical Biotechnology, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Suqian Scientific Research Institute of Nanjing University Medical School, Medical School, Nanjing University, Nanjing, 210008, China. guociliang@163.com.
Xiaosong GuJinan Microecological Biomedicine Shandong Laboratory, Building 1, Jinan Medical and Health Science and Technology Innovation Industrial Park, Jinan, 250000, China. nervegu@ntu.edu.cn.
Junhua WuJinan Microecological Biomedicine Shandong Laboratory, Shandong First Medical University, Jinan, 250117, China. wujunhua@nju.edu.cn.
Chunping JiangState Key Laboratory of Pharmaceutical Biotechnology, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Suqian Scientific Research Institute of Nanjing University Medical School, Medical School, Nanjing University, Nanjing, 210008, China. chunpingjiang@nju.edu.cn.

Funding

National Natural Science Foundation of China 82272819 and 81972888Primary Research and Development Plan of Jiangsu Province BE2022840Research Project of Jinan Microecological Biomedicine Shandong Laboratory JNL-2023017DResearch Project of Jinan Microecological Biomedicine Shandong Laboratory JNL-2025008BResearch Project of Jinan Microecological Biomedicine Shandong Laboratory JNL-2025009BResearch Project of Jinan Microecological Biomedicine Shandong Laboratory JNL-2025011BShandong Provincial Laboratory Project SYS202202Shandong Provincial Natural Science Foundation ZR2025MS1306the Key R&D Program of Shandong Province 2025CXPT176
6 · The paper itself

Abstract

backgroundThe efficacy of oncolytic adenoviruses (ADVs) in colorectal cancer (CRC) is limited by their inability to effectively expand CD4

methodsWe constructed an oncolytic adenovirus expressing inducible T cell co-stimulator ligand (ICOSL), designated ADV-ICOSL, based on the backbone virus ADV-NC. Its antitumor efficacy, safety, and ability to induce immunological memory were systematically evaluated in MC38 and CT26 murine colorectal cancer (CRC) models. The mechanism of action was investigated using flow cytometry, co-culture assays, RNA sequencing, and specific pathway inhibitors. The synergistic potential with anti-PD-1 or chimeric antigen receptor T cell (CAR-T) therapy was assessed. Furthermore, a humanized ICOSL-expressing virus (ADV-hICOSL) was developed and validated in cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models.

resultsWe initially discovered that ADV-NC treatment led to decreased ICOSL levels in the TME, resulting in insufficient co-stimulation for CD4

conclusionsOur study not only reveals that the suboptimal efficacy of conventional oncolytic adenovirus is associated with ICOSL downregulation and impaired CD4

Indexed as

AdenoviridaeCD4-Positive T-LymphocytesColorectal NeoplasmsImmunotherapy, AdoptiveOncolytic VirotherapyOncolytic VirusesProgrammed Cell Death 1 ReceptorAnimalsCell Line, TumorFemaleHumansMiceTumor MicroenvironmentXenograft Model Antitumor AssaysProgrammed Cell Death 1 ReceptorCAR-TCD4+ TIL-2Inducible T-cell costimulator ligand (ICOSL)Oncolytic virusPD-1T cell

Identifiers

PMID42374450
PMCPMC13579906

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.